M. R. Sertoli

963 total citations
26 papers, 638 citations indexed

About

M. R. Sertoli is a scholar working on Oncology, Cancer Research and Dermatology. According to data from OpenAlex, M. R. Sertoli has authored 26 papers receiving a total of 638 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 6 papers in Cancer Research and 5 papers in Dermatology. Recurrent topics in M. R. Sertoli's work include Cancer Treatment and Pharmacology (5 papers), Neutropenia and Cancer Infections (4 papers) and Breast Cancer Treatment Studies (4 papers). M. R. Sertoli is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Neutropenia and Cancer Infections (4 papers) and Breast Cancer Treatment Studies (4 papers). M. R. Sertoli collaborates with scholars based in Italy, United States and United Kingdom. M. R. Sertoli's co-authors include R. Rosso, Lucia Del Mastro, M. Venturini, Paola Queirolo, Emilio Bajetta, M.G. Bernengo, Gianfilippo Bertelli, B. Giannotti, Maria Giulia Zampino and Rita Lionetto and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

M. R. Sertoli

26 papers receiving 615 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. R. Sertoli Italy 11 391 185 141 98 87 26 638
Robert D. Legare United States 14 449 1.1× 72 0.4× 150 1.1× 75 0.8× 90 1.0× 35 822
Ian Mak United Kingdom 9 147 0.4× 179 1.0× 230 1.6× 178 1.8× 154 1.8× 11 591
Zaid Abdel Rahman United States 9 350 0.9× 126 0.7× 67 0.5× 186 1.9× 25 0.3× 38 570
A.B.W. Nethersell United Kingdom 14 157 0.4× 99 0.5× 117 0.8× 70 0.7× 45 0.5× 30 523
Volker Moebus Germany 15 393 1.0× 51 0.3× 164 1.2× 95 1.0× 144 1.7× 52 705
A. M. Gianni Italy 15 294 0.8× 63 0.3× 109 0.8× 160 1.6× 19 0.2× 26 619
Vittorio Silingardi Italy 12 342 0.9× 87 0.5× 115 0.8× 80 0.8× 12 0.1× 28 619
C. G. A. Price United Kingdom 13 589 1.5× 202 1.1× 123 0.9× 154 1.6× 61 0.7× 15 1.1k
U. Matulonis United States 9 342 0.9× 126 0.7× 125 0.9× 43 0.4× 122 1.4× 33 596
R Algeri Italy 13 222 0.6× 44 0.2× 44 0.3× 51 0.5× 63 0.7× 25 449

Countries citing papers authored by M. R. Sertoli

Since Specialization
Citations

This map shows the geographic impact of M. R. Sertoli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. R. Sertoli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. R. Sertoli more than expected).

Fields of papers citing papers by M. R. Sertoli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. R. Sertoli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. R. Sertoli. The network helps show where M. R. Sertoli may publish in the future.

Co-authorship network of co-authors of M. R. Sertoli

This figure shows the co-authorship network connecting the top 25 collaborators of M. R. Sertoli. A scholar is included among the top collaborators of M. R. Sertoli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. R. Sertoli. M. R. Sertoli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bedognetti, Davide, Yingdong Zhao, Lorenzo Uccellini, et al.. (2013). CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. British Journal of Cancer. 109(9). 2412–2423. 101 indexed citations
2.
Vecchio, Michele Del, Roberta Mortarini, Stefania Canova, et al.. (2010). Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors. Clinical Cancer Research. 16(23). 5862–5872. 44 indexed citations
3.
Mastro, Lucia Del, Luca Boni, M. R. Sertoli, et al.. (2005). Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Annals of Oncology. 17(1). 74–78. 78 indexed citations
4.
Pronzato, P., Paola Queirolo, Rita Lionetto, et al.. (2000). Thymidine Labeling Index Analysis in Early Breast Cancer Patients Randomized to Receive Perioperative Chemotherapy. Oncology. 60(1). 88–93. 4 indexed citations
5.
Nicolò, Massimo, et al.. (1999). Follicular large-cell lymphoma of the orbit: a clinicopathologic, immunohistochemical and molecular genetic description of one case. Graefe s Archive for Clinical and Experimental Ophthalmology. 237(7). 606–606. 4 indexed citations
6.
Miele, Mariangela, Stefano Bonassi, S. Bonatti, et al.. (1998). Micronucleus analysis in peripheral blood lymphocytes from melanoma patients treated with dacarbazine.. PubMed. 18(3B). 1967–71. 9 indexed citations
7.
Clahsen, P C, C J van de Velde, Aron Goldhirsch, et al.. (1997). Overview of randomized perioperative polychemotherapy trials in women with early-stage breast cancer.. Journal of Clinical Oncology. 15(7). 2526–2535. 26 indexed citations
8.
9.
Bajetta, Emilio, Angelo Di Leo, Maria Giulia Zampino, et al.. (1994). Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.. Journal of Clinical Oncology. 12(4). 806–811. 108 indexed citations
10.
Pronzato, P., A. Rubagotti, D. Amoroso, et al.. (1993). Second-Line Hormonotherapy for Breast Cancer. American Journal of Clinical Oncology. 16(6). 522–525. 8 indexed citations
11.
Pronzato, P., Loredana Miglietta, A. Rubagotti, et al.. (1993). Impact of Irradiation of Residual Breast on Adjuvant Chemotherapy Dose Intensity. American Journal of Clinical Oncology. 16(1). 58–60. 5 indexed citations
12.
13.
Pronzato, P., D. Amoroso, Gianfilippo Bertelli, et al.. (1991). Chemotherapy with mitomycin-C, epidoxorubicin and vinblastine in CMF failing breast cancer patients.. PubMed. 10(6). 1743–5. 2 indexed citations
14.
Pronzato, P., Paola Queirolo, D. Amoroso, et al.. (1991). Continuous Venous Infusion of Vinblastine in Metastatic Breast Cancer. Chemotherapy. 37(2). 146–149. 2 indexed citations
15.
Sertoli, M. R., Milena Bruzzone, Maria Teresa Nobile, et al.. (1991). A phase I study of recombinant interleukin-2 intraperitoneal infusion in patients with neoplastic ascites: toxic effects and immunologic results.. PubMed. 14(3). 231–7. 7 indexed citations
16.
Sertoli, M. R., M.G. Bernengo, Andrea Ardizzoni, et al.. (1989). Phase II Trial of Recombinant Alpha-2b Interferon in the Treatment of Metastatic Skin Melanoma. Oncology. 46(2). 96–98. 29 indexed citations
17.
Merlano, Marco, R. Rosso, M. R. Sertoli, et al.. (1988). Sequential versus alternating chemotherapy and radiotherapy in stage III-IV squamous cell carcinoma of the head and neck: a phase III study.. Journal of Clinical Oncology. 6(4). 627–632. 32 indexed citations
18.
Pronzato, P., Andrea Ardizzoni, Pierfranco Conté, et al.. (1986). A phase II study of mitoxantrone in advanced breast cancer.. PubMed. 5(3). 150–3. 3 indexed citations
19.
Conté, Pierfranco, M. R. Sertoli, Milena Bruzzone, et al.. (1985). Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer. Gynecologic Oncology. 20(3). 290–297. 26 indexed citations
20.
Sertoli, M. R., Ferdinando Cafiero, & Elisabetta Campora. (1982). A randomized trial of systemic versus oral prophylactic antibiotic treatment in colo-rectal surgery. 1(5). 375–378. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert D. Legare Breakdown of academic impact, for papers by Ian Mak Breakdown of academic impact, for papers by Zaid Abdel Rahman Breakdown of academic impact, for papers by A.B.W. Nethersell Breakdown of academic impact, for papers by Volker Moebus Breakdown of academic impact, for papers by A. M. Gianni Breakdown of academic impact, for papers by Vittorio Silingardi Breakdown of academic impact, for papers by C. G. A. Price Breakdown of academic impact, for papers by U. Matulonis Breakdown of academic impact, for papers by R Algeri
Rankless by CCL
2026